After Alnylam presented new Phase 2 open-label extension data for lumasiran in primary hyperoxaluria type 1 patients, Piper Jaffray analyst Edward Tenthoff said he believes that lumasiran could become Alnylam’s third approved RNAi drug after the expected approval in 2020 of givosiran to combine with currently marketed Onpattro. The analyst, who projects lumasiran to launch in 2021 and for sales to exceed $1B by 2024, keeps an Overweight rating and $142 price target on Alnylam shares.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.